Shanghai Henlius Biotech
Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€1.8b (Public information from Sep 2024)
Share price
HKD23 2696.HK
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 588m | 1.7b | 3.2b | 5.4b | 5.9b | 6.5b | 7.4b |
| % growth | 546 % | 186 % | 91 % | 68 % | 9 % | 10 % | 15 % |
| EBITDA | (814m) | (672m) | (309m) | 1.1b | 1.1b | 1.2b | 1.4b |
| % EBITDA margin | (139 %) | (40 %) | (10 %) | 20 % | 18 % | 19 % | 19 % |
| Profit | (994m) | (984m) | (695m) | 546m | 594m | 710m | 887m |
| % profit margin | (169 %) | (58 %) | (22 %) | 10 % | 10 % | 11 % | 12 % |
| EV / revenue | 37.8x | 5.8x | 1.9x | 1.3x | 1.9x | 1.8x | 1.5x |
| EV / EBITDA | -27.3x | -14.5x | -19.9x | 6.4x | 10.5x | 9.4x | 8.1x |
| R&D budget | 894m | 1.0b | 1.4b | 1.1b | - | - | - |
| R&D % of revenue | 152 % | 61 % | 43 % | 21 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | - | |
$190m | Growth Equity VC | ||
$156m Valuation: $2.9b | Growth Equity VC | ||
| N/A | $410m | IPO | |
* | N/A Valuation: $1.7b | Acquisition | |
| Total Funding | €315m | ||
Related Content
Recent News about Shanghai Henlius Biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.